glycyl-arginyl-glycyl-aspartyl-serine has been researched along with fluorescein-5-isothiocyanate in 1 studies
| Studies (glycyl-arginyl-glycyl-aspartyl-serine) | Trials (glycyl-arginyl-glycyl-aspartyl-serine) | Recent Studies (post-2010) (glycyl-arginyl-glycyl-aspartyl-serine) | Studies (fluorescein-5-isothiocyanate) | Trials (fluorescein-5-isothiocyanate) | Recent Studies (post-2010) (fluorescein-5-isothiocyanate) |
|---|---|---|---|---|---|
| 190 | 0 | 42 | 8,493 | 33 | 2,090 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, TF; Lin, CH; Peng, HC; Sheu, JR | 1 |
1 other study(ies) available for glycyl-arginyl-glycyl-aspartyl-serine and fluorescein-5-isothiocyanate
| Article | Year |
|---|---|
Triflavin, an Arg-Gly-Asp-containing peptide, inhibits the adhesion of tumor cells to matrix proteins via binding to multiple integrin receptors expressed on human hepatoma cells.
Topics: Antibodies, Monoclonal; Carcinoma, Hepatocellular; Cell Adhesion; Extracellular Matrix; Flow Cytometry; Fluorescein-5-isothiocyanate; Fluorescent Antibody Technique; Fluorescent Antibody Technique, Indirect; Humans; Integrins; Liver Neoplasms; Oligopeptides; Peptides; Platelet Aggregation Inhibitors; Tumor Cells, Cultured | 1996 |